Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer and Response to Checkpoint Inhibition.

Zang, Peter D; Chawla, Neal S; Barragan-Carrillo, Regina; Chehrazi-Raffle, Alex; Tripathi, Abhishek; Pal, Sumanta K; Dorff, Tanya B

Zang, Peter D; Chawla, Neal S; Barragan-Carrillo, Regina; Chehrazi-Raffle, Alex; Tripathi, Abhishek; Pal, Sumanta K; Dorff, Tanya B.

Affiliation

Zang PD; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California.
Chawla NS; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California.
Barragan-Carrillo R; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California.
Chehrazi-Raffle A; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California.
Tripathi A; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California.
Pal SK; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California.
Dorff TB; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California.

JAMA Oncol ; 10(4): 531-532, 2024 Apr 01.

Article in En | MEDLINE | ID: mdl-38329743

This single-center cohort study assesses the association of tumor mutational burden status in patients with metastatic castration-resistant prostate cancer and response to immune checkpoint inhibitor therapy.

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms, Castration-Resistant Type of study: Observational_studies / Risk_factors_studies Limits: Humans / Male Language: En Journal: JAMA Oncol Year: 2024 Document type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google